Tag: KEYTRUDA
Moderna and Merck Announce mRNA-4157 (V940) in Combination With KEYTRUDA® (pembrolizumab) Demonstrated Meaningful Improvement in Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD out [...]
1 / 1 POSTS